Monash IVF Group (ASX:MVF) has moved firmly into the spotlight after cutting its earnings guidance for the financial year, citing weaker-than-expected demand across the Australian fertility market. For a company that operates in one of healthcare’s most emotionally significant and historically resilient niches, a profit downgrade is the kind of development that forces investors to ask harder questions.

Is this a temporary soft patch, or is the fertility stock facing a genuine demand shock? And what does the revised outlook mean for the Monash IVF share price and the broader assisted reproduction sector on the ASX?

This article explains the news, why Monash IVF is in focus, the possible…